B Rack
Overview
Explore the profile of B Rack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hauner D, Gunther J, Schederecker F, Donik L, Meyer D, Hermsdorfer J, et al.
Clin Nutr
. 2024 Nov;
43(12):243-244.
PMID: 39520784
No abstract available.
2.
Muller V, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, et al.
ESMO Open
. 2021 Nov;
6(6):100299.
PMID: 34839105
Background: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive...
3.
Hack C, Haberle L, Brucker S, Janni W, Volz B, Loehberg C, et al.
Breast
. 2020 Jan;
50:11-18.
PMID: 31958661
Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e.g., with letrozole. Letrozole often induces...
4.
Ignatiadis M, Litiere S, Rothe F, Riethdorf S, Proudhon C, Fehm T, et al.
Ann Oncol
. 2018 Jun;
29(8):1777-1783.
PMID: 29893791
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of circulating tumor cells (CTCs) in women with...
5.
Hein A, Rack B, Li L, Ekici A, Reis A, Lux M, et al.
Geburtshilfe Frauenheilkd
. 2017 Aug;
77(6):651-659.
PMID: 28757652
Large-scale genotyping studies have identified over 70 single nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk. However, knowledge regarding genetic risk factors associated with the prognosis is limited. The...
6.
Trapp E, Steidl J, Rack B, Kupka M, Andergassen U, Juckstock J, et al.
Breast
. 2017 Jul;
35:130-135.
PMID: 28732324
Background: Premenopausal women undergoing chemotherapy are at high risk for premature ovarian failure and its long-term consequences. Data on potential markers to evaluate ovarian reserve pre- and posttreatment are limited....
7.
Jaeger B, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D, et al.
PLoS One
. 2017 Jun;
12(6):e0173593.
PMID: 28586395
Background: HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating...
8.
Schroder L, Rack B, Sommer H, Koch J, Weissenbacher T, Janni W, et al.
Geburtshilfe Frauenheilkd
. 2016 May;
76(5):542-550.
PMID: 27239063
This paper aims to evaluate the toxicity profile of additive gemcitabine to adjuvant taxane-based chemotherapy in breast cancer patients. Patients enrolled in this open-label randomized controlled Phase III study were...
9.
Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, et al.
Br J Cancer
. 2016 Apr;
114(8):863-71.
PMID: 27031854
Background: Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and tolerability of epirubicin (E)/cyclophosphamide (C) followed by docetaxel (Doc) with a...
10.
Schindlbeck C, Andergassen U, Jueckstock J, Rack B, Janni W, Jeschke U
J Cancer Res Clin Oncol
. 2016 Jan;
142(9):1883-95.
PMID: 26825607
Introduction: From the early days of pathology back in the nineteenth century until now, there has been an ongoing search for the missing link between solid tumors such as breast...